TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Posttraumatic Stress Diagnostic Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of responder to the therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Progression free rate after 6 months of treatment
Endpoint domain: Mortality/survival
Primary endpoint: Expression of insulin receptor isoforms A and B
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change in Length-for-age Z scores (LAZ)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of patients receiving appropriate lipid lowering therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean concentrations of anti-<phi>X174 antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: stem cell mobilization and differentiation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: recurrence of any VT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Immunogenicity detected by plaque reduction neutralization test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in Necrotic Tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hirsutism
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Polycystic ovaries
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Menstrual irregularities
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Incremental cancer detection rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: inter-rater reliability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: changes in acute pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Wheal size diameter
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Index of Tissue Sensitivity to Insulin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Mean Blood Oxygen Level Dependent (BOLD) Percent Signal Change During Facial Affect Recognition Task
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Mean Blood Oxygen Level Dependent (BOLD) Percent Signal Change During Threat Processing Task
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Mean Blood Oxygen Level Dependent (BOLD) Percent Signal Change During Card Guessing Task
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Skin Conductance Response (SCR) During fMRI Tasks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Skin Conductance Response (SCR) During the Threat Processing Task
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Post transplantation outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Health professional resilience
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Endotracheal tube position
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Prevalence of gall bladder diseases
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Mean home blood pressure (systolic and diastolic)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Total Number of Standard Drinks Per Day Consumed During Natural Conditions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total Number of Drinks Under Controlled Conditions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Amount of sodium channel splice variants
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tissue destruction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Greatest dimension of the Cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in Forced Expiratory Volume in One Second (FEV1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Disease remission (CDAI at or below 150)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Keratinized tissue width (KTW)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Keratinized tissue thickness (KTT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change in First Peak Knee Adduction Moment (KAM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in Serum COMP Biomarker Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of solicited reactogenic side effects
Endpoint domain: Adverse events/effects
Primary endpoint: Occurrence of vaccine-related, non-solicited adverse events for facial nerve disturbance
Endpoint domain: Adverse events/effects
Primary endpoint: Occurrence of vaccine-related, non-solicited adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Minimum level of ProCalcitonin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Long-term adherence to study treatments
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Need of dialysis
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: PACU unit length of stay
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Change in proportion of beneficial bacteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plaque Reduction Neutralization Test (PRNT) Geometric Mean Titer (GMT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Maximum Lesion Area (MLA) in mm2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Continuous Performance Test (CPT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Repeatable Battery for the Assessment of Neuropsychological Status (RBANS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Stroop Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Neuropsychological Assessment Battery-Digits Forward/Digits Backward Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Incidence of PND seven days after surgery
Endpoint domain: Adverse events/effects
Primary endpoint: Post-vaccination GMT by HI assay for common strains
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Seroconversion rate by HI assay for common strains
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Seroconversion rate by HI assay for exclusive strain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: improvement in the severity of OCD symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients achieving HIV-1 RNA levels below 50 copies/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: patient reported acceptability of treatment
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Testosterone concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Central Motor Excitability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Peripheral Motor Excitability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Decline in cognitive performances
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Sputum Culture Conversion Rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Edinburgh Postpartum Depression Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Maternal Attachment Scale
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Total Lesion Average SUVMax
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total time to perform the spinal
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Area under the plasma concentration-time curve from time zero to the last measured concentration (AUClast)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration-time curve from time zero to extrapolated infinite time (AUCinf)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of life (scale)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Number of Participants With Progressive Disease or Death Due to Any Cause
Endpoint domain: Mortality/survival
Primary endpoint: Percentage of Participants in Amenorrhea
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage Change From Baseline in Total Uterine Fibroid System Quality of Life Survey System Severity (UFS-SSS) Score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change From Baseline in Pictorial Blood Loss Assessment Chart (PBAC) Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain rating scales
Endpoint domain: Life impact
Endpoint subdomain: Pain
Primary endpoint: Area Under the Plasma Concentration Versus Time Curve (AUC) From Time Zero to Infinity (0-∞)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Brief Pain Inventory (BPI) 24-hour Average Rating
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Post operative cognitive dysfunction
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Subjective pain at 24 hours post operation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum Estradiol Levels by Cycle Day
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Serum Follicle Stimulating Hormone (FSH) Levels by Cycle Day
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Serum Inhibin-B Levels by Cycle Day
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Changes in systolic and diastolic blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Pain Level Twenty Four Hours After Delivery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Survival Rate at 100 Days Post-transplant
Endpoint domain: Mortality/survival
Primary endpoint: Level of Hsp27 protein
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Trough Dabigatran Plasma Concentrations (C Trough,ss)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in MN-RET in the blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Percentage of Patients Attending a Primary Care Visit
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Percentage of Kept Divided by Scheduled Primary Care Visits
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Maximum observed plasma concentration (Cmax) of aldafermin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the concentration-time curve from time zero extrapolated to infinity (AUC 0-infinity) of aldafermin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: First hematological complete remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: methadone concentrations in breast milk
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: methadone concentrations in maternal plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Physiological effects of bup
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of cesarean sections
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Composite renal and cardiovascular endpoint
Endpoint domain: Mortality/survival
Primary endpoint: >30% decrease in the GFR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Dialysis, transplantation, death or CV event
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Drug-related toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Stenosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Plasma concentration of bupivacaine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of IV ABx courses
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: change in %FEV1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Administrative burden of the trial
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Success of recruitment rates
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of transfused units required
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: 3-month cost analysis per patient
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: High-resolution images of retina
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: immune function assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: BOLD fMRI contrast (beta value)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: z-score acquired during resting state fMRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Objectively assessed physical activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Arterial Partial Pressure of Sevoflurane
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: End Tidal Partial Pressure of Sevoflurane
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Antitumor effect (tumor size reduction)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Biomarkers evaluation of melasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Photographic evaluation of melasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical evaluation of melasma by P.G.A. scales
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Spontaneous breathing trial failure rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change of LDL-C levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Histological clearance of dysplasia/metaplasia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of radical resection (R0)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: 13C-breath test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Prevalence of genetic variants for IL28B SNPs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum concentration (Cmax) of ivermectin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to maximum concentration (Tmax) of ivermectin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the curve (AUC) of ivermectin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of radiation optic neuropathy
Endpoint domain: Adverse events/effects
Primary endpoint: Delay of occurrence of radiation optic neuropathy
Endpoint domain: Adverse events/effects
Primary endpoint: Cumulative Survival
Endpoint domain: Mortality/survival
Primary endpoint: Number of participants not manifesting a thermal lesion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Need for suture
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of participants with treatment-related hypothyroidism
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change From Study Baseline in Computerized Cognitive Battery Domain Score: Detection Test (DET) Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Percentage of Participants Based on Columbia-Suicide Severity Rating Scale (C-SSRS) Score
Endpoint domain: Adverse events/effects
Primary endpoint: Presence of D-CEC at time of engraftment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: GVHD manifestations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Heartburn or epigastric pain severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Harris Hip Functional score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: ocular safety
Endpoint domain: Adverse events/effects
Primary endpoint: systemic safety
Endpoint domain: Adverse events/effects
Primary endpoint: Worst pain VAS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time taken for recovery from Anesthesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Parasite Reduction Ratio (PRR) Assessed Through Quantitative Polymerase Chain Reaction (qPCR) Analysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Maximum Observed Plasma Concentration (Cmax) of M5717
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in objective measure of degree of physical activity
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Number of Participants with Adverse events and Serious adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Number of patients with clinically relevant findings in 12-lead ECG (electrocardiogram)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of patients with clinically relevant laboratory findings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Treatment Emergent Non-Serious Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Aortic wall inflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Sleep ratio of EEG power changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Levels changes of plasma melatonin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Pain-Related Interference
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in Quality of Recovery Score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Response Rate (Complete Response + Partial Response)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in degree of health anxiety
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Cure from severe health anxiety
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: better clinical responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Daily and total mg of opiate pain medication
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Daily and total mg of over the counter alternate pain medication
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: hypertension / blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: glucose tolerance / insulin resistance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Peak pain intensity measured by visual analog scale (VAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Functional improvement by Timed Up and Go test
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Total post-surgical opioid consumption (in MSO4 equivalents)
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Discrimination of tumorous and non-tumorous tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of bevacizumab-800CW administration
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of composite endpoint of DVT and PE events
Endpoint domain: Mortality/survival
Primary endpoint: Incidence of major and clinically relevant non-major bleeding
Endpoint domain: Adverse events/effects
Primary endpoint: Difference in iron absorption (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes